Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Concurrent Chemotherapy with Reirradiation for Head and Neck Cancer

Concomitant chemotherapy with reirradiation offers a cure for select patients with recurrent head and neck cancer in a previously irradiated area. With the findings of 2-year survival in 25% of patients, the researchers noted the importance of choosing the correct patients for this therapy. Previous concurrent chemoradiotherapy was associated with poor survival outcomes. In addition, there was significant risk of sever toxicity, with 20% of patients experiencing treatment-related death.

 

The complete study is published online in the journal Cancer (http://onlinelibrary.wiley.com/doi/10.1002/cncr.26084/abstract).

Related Items
November 4, 2019 — Oncology News & Updates
Web Exclusives published on November 5, 2019 in Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Oral Cancer and Sex in the Era of HPV Infection
Meg Barbor, MPH
Web Exclusives published on October 28, 2019 in Head and Neck Cancer
Biopsy of Sentinel Lymph Node Considered Safe and Effective in Head and Neck Melanomas
TON - Daily published on August 8, 2011 in Head and Neck Cancer
Concurrent Chemotherapy with Reirradiation for Head and Neck Cancer
TOP - Daily published on June 17, 2011 in Head and Neck Cancer
Infrastructure Issues in the US Drug Supply: Where Did the Drugs Go?
Timothy G. Tyler, PharmD, FCSHP
JHOP - March 2011, Vol 1, No 1 published on March 22, 2011 in Head and Neck Cancer
Last modified: April 27, 2020